Navigation Links
Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
Date:9/9/2008

HAYWARD, Calif., Sept. 9 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the appointment of Kenneth Luskey, M.D. to the newly created position of Vice President, Clinical Research reporting to K. Alice Leung, the Company's CEO. In his new role, Dr. Luskey will lead the clinical development of Intarcia's proprietary drug development programs including Omega DUROS(R) therapy for hepatitis C and ITCA 650 for the treatment of type 2 diabetes.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO)

Dr. Luskey has extensive experience in endocrinology and metabolism research, as well as in drug development. He spent more than 13 years in academic medicine prior to holding leadership positions with several biopharmaceutical companies where he directed the development of new therapies for the treatment of diabetes. Dr. Luskey began his career at the National Institutes of Health before completing a fellowship and receiving a faculty appointment at the University of Texas Southwestern Medical School. While in Dallas, he worked extensively with Drs. Joseph L. Goldstein and Michael Brown, winners of the Nobel Prize in Medicine in 1985 for their work on cholesterol metabolism. In 1991, Dr. Luskey joined Scios, Inc. (now a member of the Johnson & Johnson family of companies) where he led research efforts to develop new treatments for diabetes and obesity. Subsequently, Dr. Luskey joined Metabolex, Inc. where he led research and drug development programs focused on diabetes and impaired glucose tolerance as Vice President, Clinical Development. Dr. Luskey also was head of experimental medicine for Tularik Inc. (subsequently acquired by Amgen Inc.), and was most recently head of preclinical and translational medicine for Nuvelo, Inc. Dr. Luskey received his medical education at the University of Texas Southwestern Medical School in Dallas. He trained in internal medicine with a subspecialty in endocrinology and metabolism.

"We are very pleased to have Ken join Intarcia Therapeutics to lead our hepatitis C and diabetes clinical development efforts," said Alice Leung. "Ken's drug development experience and expertise in the areas of diabetes and metabolic diseases are tremendous assets as we prepare to initiate clinical development of ITCA 650 for the treatment of type 2 diabetes. We look to his significant clinical and development expertise as we bring Omega DUROS therapy into later stages of development as well as expand the Company's pipeline in the metabolic diseases area."

Intarcia is currently conducting a phase 1 study of Omega DUROS therapy in combination with ribavirin for the treatment of patients with HCV genotype-1 who have failed prior standard of care treatment. In addition, Intarcia is preparing to initiate a phase 1 clinical trial of ITCA 650 in the first quarter of 2009 for the treatment of type 2 diabetes. Both of these programs use Intarcia's proprietary subcutaneous DUROS drug delivery technology that provides continuous and consistent administration of drug therapy.

Dr. Luskey said, "Intarcia represents a very unique opportunity. I believe the proven advantages of the DUROS delivery technology hold great potential in developing more effective treatments for many chronic diseases, including hepatitis C and type 2 diabetes. I am very excited to join Intarcia at this stage of the Company's development and look forward to directing clinical programs to fulfill the potential of DUROS delivery in these two disease areas."

About Intarcia

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with chronic diseases in which there are significant unmet medical needs. Intarcia's drug development expertise and competitive edge are complemented by its ability to stabilize macromolecules and to deliver them in a constant and consistent manner via the proprietary DUROS drug delivery platform. The initial programs that Intarcia is pursuing are in hepatitis C and type 2 diabetes.

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc. DUROS is a registered trademark of ALZA Corporation.


'/>"/>
SOURCE Intarcia Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics, Inc. Announces Reverse Stock Split
2. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
3. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
4. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
5. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
6. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
7. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
8. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
9. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
10. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
11. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017  GlobeImmune, Inc. today announced it ... sale of 12,835,490 shares of its common stock to ... companies. In connection with the sale of its common stock, ... and issue to GlobeImmune 200,000 shares, an estimated $2.0 ... "We are pleased to enter into this strategic ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ellen Matloff, ... Connecticut Technology Council (CTC) as a 2017 Women of Innovation® finalist. Matloff will ... Innovation Awards Dinner. , The dinner recognizes women accomplished in science, technology, engineering ...
(Date:3/23/2017)... March 23, 2017 NetworkNewsWire Editorial Coverage  ... Cancer ... significant strain on health care systems, in terms of costs ... so too does the development of innovative and efficient therapies ... Among the many types of cancer treatments, a growing number ...
(Date:3/23/2017)... 2017  Agriculture technology company Cool Planet has closed ... conversion to commercialize its Cool Terra and Cool Fauna ... products that are simultaneously profitable as well as sustainable ... 18 months. This latest round of funding was led ... The company,s primary product, Cool Terra, can ...
Breaking Biology Technology:
(Date:3/6/2017)... , March 6, 2017 ... sales technology, today announced Predictive Sales Coach TM ... infusing actionable sales intelligence into Salesforce. This unique ... enable their sales organizations with deep knowledge of ... allow for intelligent engagement. Predictive Sales Coach extends ...
(Date:3/2/2017)... Australian stem cell and regenerative medicine company, ... an agreement with the Monash Lung Biology Network, a ... and Department of Pharmacology at Monash University, ... to support the use of Cymerus™ mesenchymal stem cells ... Asthma is a chronic, long term lung condition recognised ...
(Date:2/28/2017)... 27. Februar 2017  EyeLock LLC, ein marktführendes Unternehmen ... erstklassige biometrische Lösung zur Iris-Erkennung auf der ... LTE auf dem Mobile World Congress 2017 ... in Halle 3, Stand 3E10, vorstellen. ... Qualcomm Haven™ – eine Kombination aus Hardware, ...
Breaking Biology News(10 mins):